Please enable Javascript

Labmeeting uses lots of Javascript - basically you can't use the site without it. So please enable Javascript in your browser. If your browser does not support Javascript, we recommend Firefox.

Papers authored by Felsher DW

Collect these papers and discover other ones on Labmeeting. Learn more.

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

+ cite this

+ View Abstract

Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, and Felsher DW

Nature medicine 15(5):566-71, 2009 May - Who cited this? | PubMed ID: 19363496 | Fulltext

Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds.

+ cite this

+ View Abstract

Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K, Padiernos E, Boonmark N, Zhu Z, Fan AC, Bailey AS, Fleming WH, Corless C, Felsher DW, Naumovski L, and Lopez CD

Proceedings of the National Academy of Sciences of the United States of America 106(11):4390-5, 2009 Mar 17 - Who cited this? | PubMed ID: 19251665 | Fulltext

The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse.

+ cite this

+ View Abstract

Lee HG, Casadesus G, Nunomura A, Zhu X, Castellani RJ, Richardson SL, Perry G, Felsher DW, Petersen RB, and Smith MA

The American journal of pathology 174(3):891-7, 2009 Mar - Who cited this? | PubMed ID: 19164506 | Fulltext

Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation.

+ cite this

+ View Abstract

Ney JT, Schmidt T, Kurts C, Zhou Q, Eckert D, Felsher DW, Schorle H, Knolle P, Tüting T, Barchet W, Büttner R, Limmer A, and Gütgemann I

Hepatology (Baltimore, Md.) 49(2):471-81, 2009 Feb - Who cited this? | PubMed ID: 19105207 | Fulltext

Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure.

+ cite this

+ View Abstract

Lee HG, Chen Q, Wolfram JA, Richardson SL, Liner A, Siedlak SL, Zhu X, Ziats NP, Fujioka H, Felsher DW, Castellani RJ, Valencik ML, McDonald JA, Hoit BD, Lesnefsky EJ, and Smith MA

PLoS ONE 4(9):e7172, 2009 - Who cited this? | PubMed ID: 19779629 | Fulltext

Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy.

+ cite this

Liu Z, Fan AC, Rakhra K, Sherlock S, Goodwin A, Chen X, Yang Q, Felsher DW, and Dai H

Angewandte Chemie (International ed. in English) 48(41):7668-72, 2009 - Who cited this? | PubMed ID: 19760685 | Fulltext

(18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation.

+ cite this

+ View Abstract

Arvanitis C, Bendapudi PK, Tseng JR, Gambhir SS, and Felsher DW

Cancer biology & therapy 7(12), 2008 Dec 7 - Who cited this? | PubMed ID: 18981708 | Fulltext

The current STATe of biomarkers to predict the response to anti-angiogenic therapies.

+ cite this

Tran PT and Felsher DW

Cancer biology & therapy 7(12):2004-6, 2008 Dec - Who cited this? | PubMed ID: 19158482 | Fulltext

A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice.

+ cite this

+ View Abstract

Fan AC, Goldrick MM, Ho J, Liang Y, Bachireddy P, and Felsher DW

Molecular cancer 7(1):74, 2008 Sep 30 - Who cited this? | PubMed ID: 18826639 | Fulltext

An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice.

+ cite this

+ View Abstract

Traykova-Brauch M, Schönig K, Greiner O, Miloud T, Jauch A, Bode M, Felsher DW, Glick AB, Kwiatkowski DJ, Bujard H, Horst J, von Knebel Doeberitz M, Niggli FK, Kriz W, Gröne HJ, and Koesters R

Nature medicine 14(9):979-84, 2008 Sep - Who cited this? | PubMed ID: 18724376 | Fulltext

Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

+ cite this

+ View Abstract

Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, and Felsher DW

Cancer research 68(13):5132, 2008 Jul 1 - Who cited this? | PubMed ID: 18593912 | Fulltext

Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis.

+ cite this

+ View Abstract

Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, and Felsher DW

PLoS genetics 4(6), 2008 Jun - Who cited this? | PubMed ID: 18535662 | Fulltext

Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?.

+ cite this

+ View Abstract

Felsher DW

Cancer research 68(9):3081-6; discussion 3086, 2008 May 1 - Who cited this? | PubMed ID: 18451131 | Fulltext

Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis.

+ cite this

+ View Abstract

Beer S, Komatsubara K, Bellovin DI, Kurobe M, Sylvester K, and Felsher DW

PLoS ONE 3(6), 2008 - Who cited this? | PubMed ID: 18560566 | Fulltext

Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas.

+ cite this

+ View Abstract

Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, and Felsher DW

PLoS ONE 3(5):e2125, 2008 - Who cited this? | PubMed ID: 18461184 | Fulltext

Tumor dormancy and oncogene addiction.

+ cite this

+ View Abstract

Felsher DW

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 116(7-8):629-37, 2008 - Who cited this? | PubMed ID: 18834407 | Fulltext

Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch.

+ cite this

+ View Abstract

Felsher DW

Lymphatic research and biology 6(3-4):149-54, 2008 - Who cited this? | PubMed ID: 19093787 | Fulltext

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

+ cite this

+ View Abstract

Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, and Felsher DW

Blood 110(7):2674, 2007 Oct 1 - Who cited this? | PubMed ID: 17622571 | Fulltext

Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis.

+ cite this

+ View Abstract

Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, and Leone G

Proceedings of the National Academy of Sciences of the United States of America 104(39):15400, 2007 Sep 25 - Who cited this? | PubMed ID: 17881568 | Fulltext

HIF-dependent antitumorigenic effect of antioxidants in vivo.

+ cite this

+ View Abstract

Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, and Dang CV

Cancer cell 12(3):230, 2007 Sep - Who cited this? | PubMed ID: 17785204 | Fulltext

Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.

+ cite this

+ View Abstract

Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, and Felsher DW

Proceedings of the National Academy of Sciences of the United States of America 104(32):13028, 2007 Aug 7 - Who cited this? | PubMed ID: 17664422 | Fulltext

Development of a Conditional Bioluminescent Transplant Model for TPM3-ALK-Induced Tumorigenesis as a Tool to Validate ALK-Dependent Cancer Targeted Therapy.

+ cite this

+ View Abstract

Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M, Al Saati T, Felsher DW, Delsol G, and Meggetto F

Cancer biology & therapy 6(8):1318-23, 2007 Aug - Who cited this? | PubMed ID: 17660712 | Fulltext

Identifying critical signaling molecules for the treatment of cancer.

+ cite this

Arvanitis C, Bendapudi PK, Bachireddy P, and Felsher DW

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 172:5-24, 2007 - Who cited this? | PubMed ID: 17607933 | Fulltext

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

+ cite this

+ View Abstract

Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, and Felsher DW

Proceedings of the National Academy of Sciences of the United States of America 103(44):16266, 2006 Oct 31 - Who cited this? | PubMed ID: 17056717 | Fulltext

Conditional transgenic models define how MYC initiates and maintains tumorigenesis.

+ cite this

+ View Abstract

Arvanitis C and Felsher DW

Seminars in cancer biology 16(4):313-7, 2006 Aug - Who cited this? | PubMed ID: 16935001 | Fulltext

Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models.

+ cite this

+ View Abstract

Felsher DW

Cell cycle (Georgetown, Tex.) 5(16):1808-11, 2006 Aug - Who cited this? | PubMed ID: 16929172 | Fulltext

MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species.

+ cite this

+ View Abstract

Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, and Felsher DW

Cancer research 66(13):6598, 2006 Jul 1 - Who cited this? | PubMed ID: 16818632 | Fulltext

CDK2 is required by MYC to induce apoptosis.

+ cite this

+ View Abstract

Deb-Basu D, Aleem E, Kaldis P, and Felsher DW

Cell cycle (Georgetown, Tex.) 5(12):1342-7, 2006 Jun - Who cited this? | PubMed ID: 16760655 | Fulltext

MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2.

+ cite this

+ View Abstract

Deb-Basu D, Karlsson A, Li Q, Dang CV, and Felsher DW

Cell cycle (Georgetown, Tex.) 5(12):1348-55, 2006 Jun - Who cited this? | PubMed ID: 16760657 | Fulltext

Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax.

+ cite this

+ View Abstract

Kwon H, Ogle L, Benitez B, Bohuslav J, Montano M, Felsher DW, and Greene WC

The Journal of biological chemistry 280(42):35713-22, 2005 Oct 21 - Who cited this? | PubMed ID: 16105841 | Fulltext

Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model.

+ cite this

+ View Abstract

Sander S, Bullinger L, Karlsson A, Giuriato S, Hernandez-Boussard T, Felsher DW, and Pollack JR

Oncogene 24(40):6101-7, 2005 Sep 8 - Who cited this? | PubMed ID: 16007205 | Fulltext

Conditionally MYC: insights from novel transgenic models.

+ cite this

+ View Abstract

Arvanitis C and Felsher DW

Cancer letters 226(2):95-9, 2005 Aug 26 - Who cited this? | PubMed ID: 16039948 | Fulltext

Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression.

+ cite this

+ View Abstract

Beverly LJ, Felsher DW, and Capobianco AJ

Cancer research 65(16):7159-68, 2005 Aug 15 - Who cited this? | PubMed ID: 16103066 | Fulltext

Rehabilitation of cancer through oncogene inactivation.

+ cite this

+ View Abstract

Shachaf CM and Felsher DW

Trends in molecular medicine 11(7):316-21, 2005 Jul - Who cited this? | PubMed ID: 15955741 | Fulltext

Getting at MYC through RAS.

+ cite this

Bachireddy P, Bendapudi PK, and Felsher DW

Clinical cancer research : an official journal of the American Association for Cancer Research 11(12):4278, 2005 Jun 15 - Who cited this? | PubMed ID: 15958607 | Fulltext

Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.

+ cite this

+ View Abstract

Shachaf CM and Felsher DW

Cancer research 65(11):4471-4, 2005 Jun 1 - Who cited this? | PubMed ID: 15930260 | Fulltext

Developmental context determines latency of MYC-induced tumorigenesis.

+ cite this

+ View Abstract

Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, Cardiff RD, and Felsher DW

PLoS biology 2(11):0, 2004 Nov - Who cited this? | PubMed ID: 15455033 | Fulltext

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

+ cite this

+ View Abstract

Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, and Felsher DW

Nature 431(7012):1112, 2004 Oct 28 - Who cited this? | PubMed ID: 15475948 | Fulltext

Putting oncogenes into a developmental context.

+ cite this

+ View Abstract

Felsher DW

Cancer biology & therapy 3(10):942-4, 2004 Oct - Who cited this? | PubMed ID: 15611633 | Fulltext

The human BCL6 transgene promotes the development of lymphomas in the mouse.

+ cite this

+ View Abstract

Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, and Baron JM

Proceedings of the National Academy of Sciences of the United States of America 101(39):14198-203, 2004 Sep 28 - Who cited this? | PubMed ID: 15375218 | Fulltext

Oncogenes as therapeutic targets.

+ cite this

Felsher DW

Seminars in cancer biology 14(1):1, 2004 Feb - Who cited this? | PubMed ID: 14757530 | Fulltext

Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer.

+ cite this

+ View Abstract

Giuriato S, Rabin K, Fan AC, Shachaf CM, and Felsher DW

Seminars in cancer biology 14(1):3-11, 2004 Feb - Who cited this? | PubMed ID: 14757531 | Fulltext

Reversibility of oncogene-induced cancer.

+ cite this

+ View Abstract

Felsher DW

Current opinion in genetics & development 14(1):37-42, 2004 Feb - Who cited this? | PubMed ID: 15108803 | Fulltext

Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression.

+ cite this

+ View Abstract

Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, and Felsher DW

Proceedings of the National Academy of Sciences of the United States of America 100(17):9974-9, 2003 Aug 19 - Who cited this? | PubMed ID: 12909717 | Fulltext

Cancer revoked: oncogenes as therapeutic targets.

+ cite this

+ View Abstract

Felsher DW

Nature reviews. Cancer 3(5):375-80, 2003 May - Who cited this? | PubMed ID: 12724735 | Fulltext

Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.

+ cite this

+ View Abstract

Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, and Felsher DW

Blood 101(7):2797-803, 2003 Apr 1 - Who cited this? | PubMed ID: 12517816 | Fulltext

How cancers escape their oncogene habit.

+ cite this

+ View Abstract

Giuriato S and Felsher DW

Cell cycle (Georgetown, Tex.) 2(4):329-32, 2003 - Who cited this? | PubMed ID: 12851484 | Fulltext

Pharmacological inactivation of MYC for the treatment of cancer.

+ cite this

+ View Abstract

Felsher DW and Bradon N

Drug news & perspectives 16(6):370-4, 2003 - Who cited this? | PubMed ID: 12973448 | Fulltext

Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

+ cite this

+ View Abstract

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, and Felsher DW

Science (New York, N.Y.) 297(5578):102-4, 2002 Jul 5 - Who cited this? | PubMed ID: 12098700 | Fulltext

c-Myc is a critical target for c/EBPalpha in granulopoiesis.

+ cite this

+ View Abstract

Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, and Tenen DG

Molecular and cellular biology 21(11):3789-806, 2001 Jun - Who cited this? | PubMed ID: 11340171 | Fulltext

Search Google Scholar for Felsher DW

Join Labmeeting

Organize and search your PDF collection
Collect papers
Search millions of papers
Keep up to date with paper alerts
Read your papers from anywhere
Recommend papers to colleagues
Manage your lab

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.

Got a question?
The Labmeeting Network
has the answer.
Ask scientists at top universities like Harvard, Stanford, and MIT for their expert opinion!